Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHT102
- Development stage
- Phase 1
- Lead developer
- Nanjing Calmhome Cell and Gene Engineering Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CHT102 is an allogeneic universal chimeric antigen receptor T-cell (U CAR-T) immunotherapy targeting mesothelin (MSLN), a cell surface protein overexpressed in several solid tumors. Developed by Tianjin Medical University Cancer Institute and Hospital, with involvement from Nanjing Calmhome Cell & Gene Engineering Institute, this therapy is designed for the treatment of MSLN-positive advanced solid tumors, including pancreatic cancer. The drug functions as a mesothelin inhibitor through engineered CAR-T cells that recognize and attack tumor cells expressing mesothelin. As of early 2025, CHT102 is in Phase 1 clinical trials for pancreatic cancer and other MSLN-positive solid tumors[1][2][3][4][5].
- Other names
- CHT-102CHT102CHT 102
02
Targets
Mesothelin
Beyond the preview
Go deeper on CHT102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHT102.